Browse EX-10 agreements

**Exhibit 10.34 **

**AVENZO THERAPEUTICS, INC. **

August 22, 2022

Mohammad Hirmand, M.D.

[***]

Re:	**Employment Terms **

Dear Mohammad:

Avenzo Therapeutics, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Executive Vice President and Chief Medical Officer on the terms and conditions set forth in this letter agreement (the “Agreement”).

…

**Exhibit 10.33 **

**AVENZO THERAPEUTICS, INC. **

August 22, 2025

Athena M. Countouriotis, M.D.

[***]

Re:	**Employment Terms **

Dear Athena:

This letter agreement (the “Agreement”) is effective as of August 22, 2025 (the “Effective Date”) and amends and restates that certain letter agreement between you and Avenzo Therapeutics, Inc. (the “Company”) dated August 18, 2022 (the “Prior Agreement”). The terms of this Agreement supersede the terms of the Prior Agreement in their entirety.

…

**Exhibit 10.38 **

**CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE AVENZO THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO AVENZO THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. **

**AMENDMENT NO.1 TO COLLABORATION, EXCLUSIVE OPTION AND LICENSE AGREEMENT **

This AMENDMENT NO.1 TO COLLABORATION, EXCLUSIVE OPTION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of November 26, 2024 (the “Amendment Effective Date”) by and between Avenzo Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (“Avenzo”), with offices located at 12707 High Bluff Drive, Suite 200, San Diego, California 92130, United States, and VelaVigo (Shanghai) Limited, a corporation organized and existing under the laws of China (“VelaVigo”), with offices located at Building 1, 215 Fute South Rd, WGQ Free Trade Zone, Pudong, Shanghai, and for purposes of Sections 5.8 and 5.9, Article 18 and Article 19 of the License Agreeme

…

**Exhibit 10.35 **

**AVENZO THERAPEUTICS, INC. **

August 22, 2022

Brian Sun

[***]

Re:	**Employment Terms **

Dear Brian:

Avenzo Therapeutics, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Senior Vice President, Chief Legal Officer and Corporate Secretary on the terms and conditions set forth in this letter agreement (the “Agreement”).

…

**Exhibit 10.39 **

**CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE AVENZO THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO AVENZO THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. **

**COLLABORATION AND LICENSE AGREEMENT **

**by and between **

AVENZO THERAPEUTICS, INC.

**and **

**DUALITY BIOLOGICS (SUZHOU) CO., LTD. **

**dated as of December 23, 2024 **

---

**TABLE OF CONTENTS **

…

**Exhibit 10.36 **

**CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE AVENZO THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO AVENZO THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. **

**COLLABORATION AND LICENSE AGREEMENT **

**by and between **

AVENZO THERAPEUTICS, INC.

**and **

ALLORION THERAPEUTICS INC.

**dated as of January 3, 2024 **

---

**TABLE OF CONTENTS **

…

**Exhibit 10.32 **

**AVENZO THERAPEUTICS, INC. **

**COMMON STOCK PURCHASE AGREEMENT **

This Common Stock Purchase Agreement (the “Agreement”) is made as of [  ] by and between Avenzo Therapeutics, Inc., a Delaware corporation (the “Company”) and [  ] (“Purchaser”). Certain capitalized terms used below are defined in the terms and conditions set forth in Exhibit A attached to this Agreement, which are incorporated by reference.

…

**Exhibit 10.37 **

**CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE AVENZO THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO AVENZO THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. **

**COLLABORATION, EXCLUSIVE OPTION AND LICENSE AGREEMENT **

**by and between **

AVENZO THERAPEUTICS, INC.

**and **

**VELAVIGO (SHANGHAI) LIMITED **

**and **

**for purposes of Sections 5.8 and 5.9 and Articles 18 and 19, **

**VELAVIGO BIO, INC. **

**dated as of November 16, 2024 **

---

**TABLE OF CONTENTS **

…

**Exhibit 10.41 **

***FIRST AMENDMENT TO OFFICE LEASE ***

This FIRST AMENDMENT TO OFFICE LEASE (this “First Amendment”) is made and entered into as of December 6, 2024, by and between KR JUNCTION, LLC, a Delaware limited liability company (“Landlord”), and AVENZO THERAPEUTICS, INC., a Delaware corporation (“Tenant”).

R E C I T A L S :

A. Landlord (as successor-in-interest to BRE CA OFFICE OWNER LLC, a Delaware limited liability company) and Tenant entered into that certain Office Lease dated 11/7/2022 (the “Lease”), whereby Landlord leases to Tenant and Tenant leases from Landlord those certain premises consisting of 17,223 rentable square feet (collectively, the “Existing Premises”) comprised of: (i) that certain space consisting of 5,960 rentable square feet of space commonly known as Suite 250 (“Suite 250”) and located on the second (2nd) floor of that certain building (the “Building”) located at 12707 High Bluff Drive, San Diego, California 92130, and (ii) that certain space consisting of 11,263 rentable square feet of space com

…

**Exhibit 10.40 **

***OFFICE LEASE ***

11/7/2022

This Office Lease (this “Lease”) is dated November ___, 2022, by and between BRE CA OFFICE OWNER LLC, a Delaware limited liability company (“Landlord”) and AVENZO THERAPEUTICS, INC., a Delaware corporation (“Tenant”). The following exhibits are incorporated herein and made a part hereof: Exhibit A-1 (Outline of Suite 250, Suite 200, and Potential Offering Space [Suite 225]); Exhibit A-2 (Outline of Temporary Space); ***Exhibit ***B (Expenses and Taxes); Exhibit C-1 (Suite 250 Tenant Work Letter); Exhibit C-2 (Suite 200 Tenant Work Letter); ***Exhibit ***D (Form of Confirmation Letter); ***Exhibit ***E (Rules and Regulations); ***Exhibit ***F (Additional Provisions); ***Exhibit ***G (Judicial Reference); Exhibit H (Form of Letter of Credit); Exhibit I (Approximate Location of Signage).

**1 BASIC LEASE INFORMATION. **

1.1 Premises.

…

**Exhibit 10.31 **

**AVENZO THERAPEUTICS, INC. **

**2022 EQUITY INCENTIVE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 15, 2022| **

**APPROVED BY THE STOCKHOLDERS: AUGUST 15, 2022 **

**AMENDED BY THE BOARD OF DIRECTORS: AUGUST 17, 2022 **

**AMENDED BY THE BOARD OF DIRECTORS: SEPTEMBER 13, 2022 **

**AMENDED BY THE BOARD OF DIRECTORS: MARCH 6, 2023 **

**APPROVED BY THE STOCKHOLDERS: MARCH 6, 2023 **

**AMENDED BY THE BOARD OF DIRECTORS: MARCH 11, 2024 **

**APPROVED BY THE STOCKHOLDERS: MARCH 11, 2024 **

**AMENDED BY THE BOARD OF DIRECTORS: MARCH 21, 2024 **

**APPROVED BY THE STOCKHOLDERS: MARCH 21, 2024 **

**AMENDED BY THE BOARD OF DIRECTORS: NOVEMBER 4, 2024 **

**APPROVED BY THE STOCKHOLDERS: NOVEMBER 4, 2024 **

**AMENDED BY THE BOARD OF DIRECTORS: JUNE 6, 2025 **

**APPROVED BY THE STOCKHOLDERS: JUNE 16, 2025 **

**AMENDED BY THE BOARD OF DIRECTORS: AUGUST 21, 2025 **

**APPROVED BY THE STOCKHOLDERS: AUGUST 21, 2025 **

**AMENDED BY THE BOARD OF DIRECTORS: SEPTEMBER 17, 2025 **

**APPROVED BY THE STOCKHOLDERS: SEPTEMBER 17, 2025 **

…

** **

**INDEMNITY AGREEMENT **

THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of ________, 2026, by and between Sono Group, Inc., a Delaware corporation (the “Company”), and _________ (“Indemnitee”).

***RECITALS ***

WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of such corporations;

…